共 50 条
- [1] Effect of body mass index (BMI) on efficacy of immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 571 - 571Lynn, DavidHobeika, CharbelPatgunarajah, UbenthiraDawsey, ScottPramod, NikhilWei, WeiNair, MonicaMaroli, KimberlyMartin, AllisonOrnstein, Moshe ChaimWee, Christopher EingGilligan, Timothy D.Nizam, AmandaBonham, AmandaMian, Omar Y.Pavicic, Paul G.Diaz-Montero, C. MarcelaGupta, Shilpa
- [2] Effect of neutrophil to lymphocyte ratio (NLR) on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial carcinoma (mUC) in real-world setting.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 678 - 678Lynn, DavidDawsey, ScottPatgunarajah, UbenthiraPramod, NikhilWei, WeiHobeika, CharbelNair, MonicaMaroli, KimberlyMartin, AllisonOrnstein, Moshe ChaimWee, Christopher EingGilligan, Timothy D.Nizam, AmandaBonham, AmandaMian, Omar Y.Pavicic, Paul G.Diaz-Montero, C. MarcelaGupta, Shilpa
- [3] Effect of type of antibiotics (Abx) on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial carcinoma (mUC) in a real-world setting[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 640 - 640Hobeika, CharbelDawsey, ScottPatgunarajah, UbenthiraLynn, DavidPramod, NikhilWei, WeiNair, MonicaMaroli, KimberlyMartin, AllisonOrnstein, Moshe ChaimWee, Christopher EingGilligan, Timothy D.Nizam, AmandaBonham, AmandaMian, Omar Y.Pavicic, Paul G.Diaz-Montero, C. MarcelaGupta, Shilpa
- [4] Genomic correlates of response and resistance to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 670 - 670Pramod, NikhilMakarov, VladimirDawsey, ScottPavicic, Paul G.Patgunarajah, UbenthiraNair, MonicaOrnstein, Moshe ChaimGilligan, Timothy D.Wee, Christopher EingNizam, AmandaMian, Omar Y.Nguyen, JaneDiaz-Montero, C. MarcelaGupta, Shilpa
- [5] The effect of antibiotic (Abx) use on immune checkpoint inhibitor (ICI) efficacy in patients (pts) with metastatic urothelial carcinoma (mUC) in a real-world setting.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Patgunarajah, UbenthiraDawsey, ScottPramod, NikhilMaroli, KimberlyOrnstein, Moshe ChaimWee, Christopher EingGilligan, Timothy D.Martin, AllisonNizam, AmandaMian, Omar Y.Wei, WeiDiaz-Montero, C. MarcelaPavicic, Paul G.Nguyen, JaneGupta, Shilpa
- [6] The effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitor (ICI) efficacy in patients with metastatic urothelial carcinoma (mUC) in real-world setting.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)Gupta, ShilpaKhan, Mohammad SiddiqueRadakovich, NathanWei, WeiOrnstein, Moshe ChaimGilligan, Timothy D.Mian, Omar Y.Dawsey, Scott
- [7] Retrospective study to assess the efficacy and safety of checkpoint inhibitors in advanced urothelial carcinoma in real-world setting.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Sevillano Fernandez, ElenaPuente, JavierVidal, NataliaPinto, AlvaroGarcia Sanchez, LourdesFiorini, AldoChara Velarde, Luis EnriqueNalda Ariza, IreneCassinello, JavierRodriguez, AngelGalvan Ruiz, SarayFrancisco Rodriguez-Moreno, JuanBarquin, ArantzazuRuiz, SergioNavarro, PalomaYague, MonicaGrande, EnriqueGarcia-Donas, Jesus
- [8] Effect of antibiotic, proton pump inhibitor, H2 blocker, metformin and statin use on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial carcinoma (mUC) in a real-world setting[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Hobeika, CharbelDawsey, ScottPatgunarajah, UbenthiraLynn, DavidPramod, NikhilWei, WeiNair, MonicaMaroli, KimberlyMartin, AllisonOrnstein, Moshe ChaimWee, Christopher EingGilligan, Timothy D.Nizam, AmandaBonham, AmandaMian, Omar Y.Pavicic, Paul G., Jr.Diaz-Montero, C. MarcelaGupta, Shilpa
- [9] The impact of body mass index on survival endpoints among patients with metastatic urothelial carcinoma undergoing treatment with immune checkpoint inhibitors: A real-world multicenter analysis[J]. CANCER MEDICINE, 2024, 13 (02):Huang, Shih-YuSu, Po-JungLin, Chang-TingKuo, Ming-ChunChen, Yi-HuaWu, Chia-CheLuo, Hao-LunChen, Chien-HsuChou, Chih-ChiHuang, Chun-ChiehKuo, Chung-WenSu, Yu-Li
- [10] Association of biomarkers and outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs).[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41Reyes, Kevin R.Zhang, LiZhu, XiaolinJindal, TanyaDeshmukh, Priankade Kouchkovsky, IvanKumar, VipulMaldonado, EdwardKwon, Daniel H.Chan, EmilyPorten, Sima P.Borno, HalaBose, RohitDesai, ArpitaAggarwal, Rahul RajSmall, Eric JayFong, LawrenceChou, JonathanFriedlander, Terence W.Koshkin, Vadim S.